7ZKF
Crystal Structure of human Brachyury G177D variant in complex with CF-5-86
This is a non-PDB format compatible entry.
Summary for 7ZKF
Entry DOI | 10.2210/pdb7zkf/pdb |
Descriptor | T-box transcription factor T, N-(4-((2-fluorophenyl)(hydroxy)methyl)phenyl)acetamide, PHOSPHATE ION, ... (4 entities in total) |
Functional Keywords | brachyury, chordoma, transcription |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 20009.87 |
Authors | Newman, J.A.,Gavard, A.,Aitkenhead, H.,Imprachim, N.,Sherestha, L.,Burgess-Brown, N.A.,von Delft, F.,Bountra, C.,Gileadi, O. (deposition date: 2022-04-12, release date: 2022-06-22, Last modification date: 2025-02-26) |
Primary citation | Newman, J.A.,Gavard, A.E.,Imprachim, N.,Aitkenhead, H.,Sheppard, H.E.,Te Poele, R.,Clarke, P.A.,Hossain, M.A.,Temme, L.,Oh, H.J.,Wells, C.I.,Davis-Gilbert, Z.W.,Workman, P.,Gileadi, O.,Drewry, D.H. Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy. Nat Commun, 16:1596-1596, 2025 Cited by PubMed Abstract: Brachyury is a transcription factor that plays an essential role in tumour growth of the rare bone cancer chordoma and is implicated in other solid tumours. Brachyury is minimally expressed in healthy tissues, making it a potential therapeutic target. Unfortunately, as a ligandless transcription factor, brachyury has historically been considered undruggable. To investigate direct targeting of brachyury by small molecules, we determine the structure of human brachyury both alone and in complex with DNA. The structures provide insights into DNA binding and the context of the chordoma associated G177D variant. We use crystallographic fragment screening to identify hotspots on numerous pockets on the brachyury surface. Finally, we perform follow-up chemistry on fragment hits and describe the progression of a thiazole chemical series into binders with low µM potency. Thus we show that brachyury is ligandable and provide an example of how crystallographic fragment screening may be used to target protein classes that are difficult to address using other approaches. PubMed: 39952925DOI: 10.1038/s41467-025-56213-1 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.49 Å) |
Structure validation
Download full validation report
